These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 17254844)

  • 1. The association of plasma osteoprotegerin levels and functional outcomes post endovascular thrombectomy in acute ischemic stroke patients: a retrospective observational study.
    Park MS; Park JH; Joo A; Chang Y; Song TJ
    PeerJ; 2022; 10():e13327. PubMed ID: 35529501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.
    Fehérvári L; Frigy A; Kocsis L; Szabó IA; Szabo TM; Urkon M; Jakó Z; Nagy EE
    Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33923139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis.
    Loudon BL; Ntatsaki E; Newsome S; Halliday B; Lota A; Ali A; Malley T; Selvendran S; Aggarwal N; Lam W; Donovan J; Auger D; Raphael CE; Flynn PD; Pennell DJ; Vassiliou VS; Prasad SK
    Sci Rep; 2018 Sep; 8(1):14550. PubMed ID: 30266917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL Expression Is Increased in Circulating Mononuclear Cells of Patients with Calcific Aortic Stenosis.
    Rattazzi M; Faggin E; Bertacco E; Buso R; Puato M; Plebani M; Zaninotto M; Condotta D; Zoppellaro G; Pagliani L; Tarantini G; Iliceto S; Covolo E; Faggian G; Onorati F; Dodonov M; Daniotti A; Pantano P; Olivari Z; Benfari G; Pauletto P
    J Cardiovasc Transl Res; 2018 Aug; 11(4):329-338. PubMed ID: 29777507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.
    di Giuseppe R; Biemann R; Wirth J; Menzel J; Isermann B; Stangl GI; Fritsche A; Boeing H; Schulze MB; Weikert C
    Eur J Epidemiol; 2017 Feb; 32(2):113-123. PubMed ID: 27307249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
    Lu J; Liu F; Liu D; Du H; Hao J; Yang X; Cui W
    Exp Biol Med (Maywood); 2016 Jun; 241(11):1237-49. PubMed ID: 26908571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin as a marker of atherosclerosis in diabetic patients.
    Augoulea A; Vrachnis N; Lambrinoudaki I; Dafopoulos K; Iliodromiti Z; Daniilidis A; Varras M; Alexandrou A; Deligeoroglou E; Creatsas G
    Int J Endocrinol; 2013; 2013():182060. PubMed ID: 23401681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of left ventricular hypertrophy and remodeling in blacks.
    Coutinho T; Al-Omari M; Mosley TH; Kullo IJ
    Hypertension; 2011 Nov; 58(5):920-5. PubMed ID: 21986506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.
    Malliga DE; Wagner D; Fahrleitner-Pammer A
    Wien Med Wochenschr; 2011 Dec; 161(23-24):565-70. PubMed ID: 21870142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.
    Poulsen MK; Nybo M; Dahl J; Hosbond S; Poulsen TS; Johansen A; Høilund-Carlsen PF; Beck-Nielsen H; Rasmussen LM; Henriksen JE
    Cardiovasc Diabetol; 2011 Aug; 10():76. PubMed ID: 21838881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.
    Loncar G; Bozic B; Cvorovic V; Radojicic Z; Dimkovic S; Markovic N; Prodanovic N; Lepic T; Putnikovic B; Popovic-Brkic V
    Endocrine; 2010 Feb; 37(1):148-56. PubMed ID: 20963564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.
    Noheria A; Mosley TH; Kullo IJ
    Am J Hypertens; 2010 Jul; 23(7):767-74. PubMed ID: 20339356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.
    Corallini F; Secchiero P; Beltrami AP; Cesselli D; Puppato E; Ferrari R; Beltrami CA; Zauli G
    Cell Mol Life Sci; 2010 Apr; 67(8):1307-14. PubMed ID: 20063037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin, vascular calcification and atherosclerosis.
    Van Campenhout A; Golledge J
    Atherosclerosis; 2009 Jun; 204(2):321-9. PubMed ID: 19007931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload.
    Helske S; Kovanen PT; Lindstedt KA; Salmela K; Lommi J; Turto H; Werkkala K; Kupari M
    Eur J Heart Fail; 2007 Apr; 9(4):357-63. PubMed ID: 17254844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
    Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
    Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.